Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Johnson & Johnson COVID-19 Vaccine Approved For Use In Switzerland

By John F. Heerdink, Jr.

Reportedly, Swiss drug regulator Swissmedic has approved Johnson & Johnson’s (JNJ) COVID-19 vaccine for usage in the country, following the earlier two approved vaccines from Pfizer and BioNTech and from Moderna. Switzerland has so far not ordered J&J’s one-shot vaccine, while deliveries have begun in the United States, Europe is not slated to get the vaccine until the second quarter.

In Johnson & Johnson’s 44,000-person global trial, the vaccine proved to be 66% effective at preventing moderate-to-severe COVID-19 four weeks after inoculation. The vaccine proved 100% effective in preventing hospitalization and death. Switzerland has not yet ordered the J&J vaccine amid its first round of shot purchases, as it may not get vaccine amid supply bottlenecks until later in 2021. It has ordered around 36 million doses of vaccines, from Pfizer/BioNTech, Moderna, Novavax, CureVac, and AstraZeneca, with the approval for the last three still awaited.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: UPDATE 1-Swiss approve Johnson & Johnson COVID-19 vaccine, haven't bought any in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us